n(g),n(g')-dimethyl-l-arginine has been researched along with Coronary Disease in 33 studies
N,N-dimethylarginine: asymmetric dimethylarginine; do not confuse with N,N'-dimethylarginine
Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In patients with chronic stable coronary disease, all clinically relevant daily doses of aspirin tested, from 81 to 1300 mg, produce similar and statistically significant increases in HO-1 and decreases in ADMA." | 9.17 | Aspirin increases nitric oxide formation in chronic stable coronary disease. ( Borzak, S; DeMets, D; Hennekens, CH; Hetzel, S; Schneider, R; Schneider, W; Schröder, H; Serebruany, V, 2013) |
| "To examine the prognostic value of serum levels of asymmetric dimethylarginine (ADMA) in patients with stable coronary heart disease (CHD) thus explore a potential biomarker of "toxin syndrome" in CHD." | 7.91 | Asymmetric Dimethylarginine Predicts One-year Recurrent Cardiovascular Events: Potential Biomarker of "Toxin Syndrome" in Coronary Heart Disease. ( Chen, KJ; Chen, Z; Gao, ZY; Shang, QH; Shi, DZ; Xu, H; Yu, CA, 2019) |
| "To monitor the changes of plasma asymmetric dimethylarginine (ADMA), nitric oxide (NO), and von Willebrand factor (vWF) levels in patients with stable angina pectoris (SAP) or acute coronary syndrome (ACS) and to evaluate the correlation between ADMA and different types of coronary heart disease." | 7.76 | Correlation between plasma asymmetric dimethylarginine and different types of coronary heart disease. ( Cao, Y; Ouyang, M; Xiao, L; Yang, K; Zhang, Z, 2010) |
| "The aim of the present study was to assess the impact of reversible myocardial ischemia, provoked by acute physical activity during an exercise stress echocardiography (ESE), on nitric oxide (NOx) and asymmetric dimethylarginine (ADMA) production in patients with high risk for coronary heart disease (CHD)." | 7.76 | Impact of reversible myocardial ischaemia on nitric oxide and asymmetric dimethylarginine production in patients with high risk for coronary heart disease. ( Ilic, MD; Ilic, S; Kocic, G; Lazarevic, G; Pavlovic, R; Stefanovic, V, 2010) |
| "An increased plasma concentration of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) predicts adverse clinical outcome in patients with coronary heart disease." | 7.74 | Asymmetric dimethylarginine, smoking, and risk of coronary heart disease in apparently healthy men: prospective analysis from the population-based Monitoring of Trends and Determinants in Cardiovascular Disease/Kooperative Gesundheitsforschung in der Regi ( Baumert, J; Böger, RH; Hamraz, K; Koenig, W; Löwel, H; Maas, R; Schulze, F; Schwedhelm, E, 2007) |
| "We measured plasma levels of ADMA and related compounds, nitrate+nitrite (NO(x)), total homocysteine (tHCY) and assessed renal function and lipid profiles in 145 patients--75 with triple vessel coronary disease and 70 with no detectable coronary disease." | 7.73 | Relations between plasma asymmetric dimethylarginine (ADMA) and risk factors for coronary disease. ( Naidoo, D; Salonikas, C; Sim, AS; Wang, J; Wang, XL; Wilcken, DE, 2006) |
| "Asymmetric dimethylarginine (ADMA) is an endogenous nitric oxide synthase inhibitor, which has been associated with total and cardiovascular mortality in various clinical settings." | 5.39 | Asymmetric and symmetric dimethylarginine and risk of secondary cardiovascular disease events and mortality in patients with stable coronary heart disease: the KAROLA follow-up study. ( Böger, R; Breitling, LP; Brenner, H; Koenig, W; Maas, R; Rothenbacher, D; Schwedhelm, E; Siegerink, B; Vossen, CY, 2013) |
| "In patients with chronic stable coronary disease, all clinically relevant daily doses of aspirin tested, from 81 to 1300 mg, produce similar and statistically significant increases in HO-1 and decreases in ADMA." | 5.17 | Aspirin increases nitric oxide formation in chronic stable coronary disease. ( Borzak, S; DeMets, D; Hennekens, CH; Hetzel, S; Schneider, R; Schneider, W; Schröder, H; Serebruany, V, 2013) |
| "We investigated whether coronary artery bypass grafting affects plasma asymmetric dimethylarginine (ADMA) concentrations and whether precardioplegic hyperoxia influences ADMA release from the heart." | 5.12 | Changes of plasma asymmetric dimethylarginine levels after coronary artery bypass grafting. ( Karu, I; Starkopf, J; Zilmer, K; Zilmer, M, 2006) |
| "To examine the prognostic value of serum levels of asymmetric dimethylarginine (ADMA) in patients with stable coronary heart disease (CHD) thus explore a potential biomarker of "toxin syndrome" in CHD." | 3.91 | Asymmetric Dimethylarginine Predicts One-year Recurrent Cardiovascular Events: Potential Biomarker of "Toxin Syndrome" in Coronary Heart Disease. ( Chen, KJ; Chen, Z; Gao, ZY; Shang, QH; Shi, DZ; Xu, H; Yu, CA, 2019) |
| "To monitor the changes of plasma asymmetric dimethylarginine (ADMA), nitric oxide (NO), and von Willebrand factor (vWF) levels in patients with stable angina pectoris (SAP) or acute coronary syndrome (ACS) and to evaluate the correlation between ADMA and different types of coronary heart disease." | 3.76 | Correlation between plasma asymmetric dimethylarginine and different types of coronary heart disease. ( Cao, Y; Ouyang, M; Xiao, L; Yang, K; Zhang, Z, 2010) |
| "The aim of the present study was to assess the impact of reversible myocardial ischemia, provoked by acute physical activity during an exercise stress echocardiography (ESE), on nitric oxide (NOx) and asymmetric dimethylarginine (ADMA) production in patients with high risk for coronary heart disease (CHD)." | 3.76 | Impact of reversible myocardial ischaemia on nitric oxide and asymmetric dimethylarginine production in patients with high risk for coronary heart disease. ( Ilic, MD; Ilic, S; Kocic, G; Lazarevic, G; Pavlovic, R; Stefanovic, V, 2010) |
| "The concentration of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, is increased in patients with coronary heart disease (CHD)." | 3.75 | Stent placement in patients with coronary heart disease decreases plasma levels of the endogenous nitric oxide synthase inhibitor ADMA. ( Ajtay, Z; Awiszus, F; Bode-Böger, SM; Cziráki, A; Horváth, I; Martens-Lobenhoffer, J; Papp, L; Scalera, F; Sulyok, E; Szabo, C, 2009) |
| " We tested whether the plasma levels of (1) asymmetric dimethylarginine (ADMA), (2) cortisol/cortisone (Cl/Cn) ratio, and (3) C-peptide predicted glycemic status, coronary artery disease, and death or myocardial infarction (MI) in a nested case-control cohort (N = 850) with normal fasting glucose (< 110 mg/dL), impaired fasting glucose (110-125), or diabetic (> or = 126) status." | 3.74 | Asymmetric dimethylarginine, cortisol/cortisone ratio, and C-peptide: markers for diabetes and cardiovascular risk? ( Anderson, JL; Bair, TL; Carlquist, JF; Horne, BD; Kushnir, MM; May, HT; Muhlestein, JB; Nielson, R; Pasquali, M; Roberts, WL; Rockwood, AL; Schwarz, EL, 2007) |
| "An increased plasma concentration of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) predicts adverse clinical outcome in patients with coronary heart disease." | 3.74 | Asymmetric dimethylarginine, smoking, and risk of coronary heart disease in apparently healthy men: prospective analysis from the population-based Monitoring of Trends and Determinants in Cardiovascular Disease/Kooperative Gesundheitsforschung in der Regi ( Baumert, J; Böger, RH; Hamraz, K; Koenig, W; Löwel, H; Maas, R; Schulze, F; Schwedhelm, E, 2007) |
| "We measured plasma levels of ADMA and related compounds, nitrate+nitrite (NO(x)), total homocysteine (tHCY) and assessed renal function and lipid profiles in 145 patients--75 with triple vessel coronary disease and 70 with no detectable coronary disease." | 3.73 | Relations between plasma asymmetric dimethylarginine (ADMA) and risk factors for coronary disease. ( Naidoo, D; Salonikas, C; Sim, AS; Wang, J; Wang, XL; Wilcken, DE, 2006) |
| "G-CSF therapy induced leukocytosis and a rise in CD34+ cell levels." | 2.75 | The effects of G-CSF-induced mobilization of progenitor cells are limited by ADMA. ( Bode-Böger, SM; Goette, A; Jentsch-Ullrich, K; Lendeckel, U; Martens-Lobenhoffer, J; Scalera, F; Wolfram, O, 2010) |
| "Asymmetric dimethylarginine (ADMA) is an endogenous nitric oxide synthase inhibitor, which has been associated with total and cardiovascular mortality in various clinical settings." | 1.39 | Asymmetric and symmetric dimethylarginine and risk of secondary cardiovascular disease events and mortality in patients with stable coronary heart disease: the KAROLA follow-up study. ( Böger, R; Breitling, LP; Brenner, H; Koenig, W; Maas, R; Rothenbacher, D; Schwedhelm, E; Siegerink, B; Vossen, CY, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 21 (63.64) | 29.6817 |
| 2010's | 12 (36.36) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, H | 1 |
| Chen, Z | 1 |
| Shang, QH | 1 |
| Gao, ZY | 1 |
| Yu, CA | 1 |
| Shi, DZ | 1 |
| Chen, KJ | 1 |
| Hetzel, S | 1 |
| DeMets, D | 1 |
| Schneider, R | 1 |
| Borzak, S | 1 |
| Schneider, W | 1 |
| Serebruany, V | 1 |
| Schröder, H | 1 |
| Hennekens, CH | 1 |
| Mokhtari, Z | 1 |
| Hosseini, S | 1 |
| Miri, R | 1 |
| Baghestani, AR | 1 |
| Zahedirad, M | 1 |
| Rismanchi, M | 1 |
| Nasrollahzadeh, J | 1 |
| Ghebremariam, YT | 1 |
| Cooke, JP | 2 |
| Khan, F | 1 |
| Thakker, RN | 1 |
| Chang, P | 1 |
| Shah, NH | 1 |
| Nead, KT | 1 |
| Leeper, NJ | 1 |
| Huang, S | 1 |
| Zou, D | 1 |
| Peng, W | 1 |
| Jiang, X | 1 |
| Shao, K | 1 |
| Xia, L | 1 |
| Tang, Y | 1 |
| Surdacki, A | 1 |
| Goette, A | 1 |
| Wolfram, O | 1 |
| Jentsch-Ullrich, K | 1 |
| Martens-Lobenhoffer, J | 2 |
| Scalera, F | 2 |
| Lendeckel, U | 1 |
| Bode-Böger, SM | 2 |
| Ajtay, Z | 1 |
| Cziráki, A | 1 |
| Horváth, I | 1 |
| Papp, L | 1 |
| Sulyok, E | 1 |
| Szabo, C | 1 |
| Awiszus, F | 1 |
| Cao, Y | 1 |
| Yang, K | 1 |
| Zhang, Z | 1 |
| Ouyang, M | 1 |
| Xiao, L | 1 |
| Ilic, MD | 1 |
| Ilic, S | 1 |
| Lazarevic, G | 1 |
| Kocic, G | 1 |
| Pavlovic, R | 1 |
| Stefanovic, V | 1 |
| Meinitzer, A | 2 |
| Kielstein, JT | 1 |
| Pilz, S | 1 |
| Drechsler, C | 1 |
| Ritz, E | 1 |
| Boehm, BO | 2 |
| Winkelmann, BR | 2 |
| März, W | 2 |
| YOU, L | 1 |
| ZHAO, CX | 1 |
| SHAO, JM | 1 |
| ZHANG, L | 1 |
| WANG, DW | 1 |
| Atzeni, F | 1 |
| Turiel, M | 1 |
| Boccassini, L | 1 |
| Sitia, S | 1 |
| Tomasoni, L | 1 |
| Battellino, M | 1 |
| Marchesoni, A | 1 |
| De Gennaro Colonna, V | 1 |
| Sarzi-Puttini, P | 1 |
| Siegerink, B | 1 |
| Maas, R | 3 |
| Vossen, CY | 1 |
| Schwedhelm, E | 3 |
| Koenig, W | 2 |
| Böger, R | 1 |
| Rothenbacher, D | 1 |
| Brenner, H | 1 |
| Breitling, LP | 1 |
| Teede, HJ | 1 |
| McGrath, BP | 1 |
| Fujita, M | 1 |
| Hori, M | 1 |
| Nanto, S | 1 |
| Kitakaze, M | 1 |
| Node, K | 1 |
| Lu, TM | 1 |
| Ding, YA | 1 |
| Lin, SJ | 1 |
| Lee, WS | 1 |
| Tai, HC | 1 |
| Valkonen, VP | 1 |
| Laakso, J | 1 |
| Päivä, H | 1 |
| Lehtimäki, T | 1 |
| Lakka, TA | 1 |
| Isomustajärvi, M | 1 |
| Ruokonen, I | 1 |
| Salonen, JT | 1 |
| Laaksonen, R | 1 |
| Mügge, A | 2 |
| Hanefeld, C | 2 |
| Böger, RH | 4 |
| Suda, O | 1 |
| Tsutsui, M | 1 |
| Morishita, T | 1 |
| Tasaki, H | 1 |
| Ueno, S | 1 |
| Nakata, S | 1 |
| Tsujimoto, T | 1 |
| Toyohira, Y | 1 |
| Hayashida, Y | 1 |
| Sasaguri, Y | 1 |
| Ueta, Y | 1 |
| Nakashima, Y | 1 |
| Yanagihara, N | 1 |
| Tsuda, K | 1 |
| Nishio, I | 1 |
| Eid, HM | 1 |
| Arnesen, H | 1 |
| Hjerkinn, EM | 1 |
| Lyberg, T | 1 |
| Seljeflot, I | 1 |
| Wang, J | 1 |
| Sim, AS | 1 |
| Wang, XL | 1 |
| Salonikas, C | 1 |
| Naidoo, D | 1 |
| Wilcken, DE | 1 |
| Schnabel, R | 1 |
| Blankenberg, S | 1 |
| Lubos, E | 1 |
| Lackner, KJ | 1 |
| Rupprecht, HJ | 1 |
| Espinola-Klein, C | 1 |
| Jachmann, N | 1 |
| Post, F | 1 |
| Peetz, D | 1 |
| Bickel, C | 1 |
| Cambien, F | 1 |
| Tiret, L | 1 |
| Münzel, T | 1 |
| Schulze, F | 2 |
| Lenzen, H | 1 |
| Bartling, A | 1 |
| Osterziel, KJ | 1 |
| Goudeva, L | 1 |
| Schmidt-Lucke, C | 1 |
| Kusus, M | 1 |
| Strödter, D | 1 |
| Simon, BC | 1 |
| Daniel, WG | 1 |
| Tillmanns, H | 1 |
| Maisch, B | 1 |
| Streichert, T | 1 |
| Karu, I | 1 |
| Zilmer, K | 1 |
| Starkopf, J | 1 |
| Zilmer, M | 1 |
| Anderson, JL | 1 |
| Carlquist, JF | 1 |
| Roberts, WL | 1 |
| Horne, BD | 1 |
| May, HT | 1 |
| Schwarz, EL | 1 |
| Pasquali, M | 1 |
| Nielson, R | 1 |
| Kushnir, MM | 1 |
| Rockwood, AL | 1 |
| Bair, TL | 1 |
| Muhlestein, JB | 1 |
| Seelhorst, U | 1 |
| Wellnitz, B | 1 |
| Halwachs-Baumann, G | 1 |
| Baumert, J | 1 |
| Löwel, H | 1 |
| Hamraz, K | 1 |
| Potena, L | 1 |
| Ferrara, R | 1 |
| Mocarski, ES | 1 |
| Lewis, DB | 1 |
| Grigioni, F | 1 |
| Coccolo, F | 1 |
| Magnani, G | 1 |
| Fallani, F | 1 |
| Magelli, C | 1 |
| Valantine, HA | 1 |
| Branzi, A | 1 |
| Verhoeven, MO | 1 |
| Teerlink, T | 1 |
| Kenemans, P | 1 |
| Zuijdgeest-van Leeuwen, SD | 1 |
| van der Mooren, MJ | 1 |
| Kiani, AN | 1 |
| Mahoney, JA | 1 |
| Petri, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation & Endothelial Function in Secondary Prevention (Pts w/Chronic Stable Coronary Disease)[NCT00272337] | Phase 4 | 37 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| Do Proton Pump Inhibitors (PPIs) Increase Cardiovascular Risk? Effect of PPIs on Endothelial Function and ADMA.[NCT02022280] | Phase 1 | 21 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Heme oxygenase a downstream target of nitric oxide formation (NCT00272337)
Timeframe: Baseline to 3 Months (90-97 days)
| Intervention | ng/mL (Mean) |
|---|---|
| 1 of 5 Randomized Treatment Arms | 10.0 |
| 2 of 5 Randomized Treatment Arms | 11.2 |
| 3 of 5 Randomized Treatment Arms | 10.0 |
| 4 of 5 Randomized Treatment Arms | 11.0 |
| 5 of 5 Randomized Treatment Arms | 9.6 |
6 reviews available for n(g),n(g')-dimethyl-l-arginine and Coronary Disease
| Article | Year |
|---|---|
L-arginine analogs--inactive markers or active agents in atherogenesis?
Topics: Arginine; Atherosclerosis; Biomarkers; Coronary Disease; Endothelium, Vascular; Humans; Inflammation | 2008 |
Cardiovascular involvement in psoriatic arthritis.
Topics: Antirheumatic Agents; Arginine; Arthritis, Psoriatic; Coronary Circulation; Coronary Disease; Cytoki | 2011 |
[ADMA (asymmetric dimethyl arginine) and coronary artery disease].
Topics: Animals; Arginine; Coronary Disease; Humans | 2003 |
Plasma concentration of asymmetric dimethylarginine and the risk of coronary heart disease: rationale and design of the multicenter CARDIAC study.
Topics: Arginine; Coronary Disease; Endothelium, Vascular; Enzyme Inhibitors; Follow-Up Studies; Humans; Nit | 2003 |
[Asymmetrical methylarginine (ADMA) as a cardiovascular risk factor: epidemiological and prospective data].
Topics: Adult; Aged; Aged, 80 and over; Animals; Arginine; Arteriosclerosis; Biomarkers; Cardiovascular Dise | 2004 |
[Coronary allograft vasculopathy: pathophysiological interaction between the immune system, infections and metabolic syndrome].
Topics: Animals; Arginine; Clinical Trials as Topic; Coronary Disease; Cytomegalovirus Infections; Disease M | 2007 |
7 trials available for n(g),n(g')-dimethyl-l-arginine and Coronary Disease
| Article | Year |
|---|---|
Aspirin increases nitric oxide formation in chronic stable coronary disease.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arginine; Aspirin; Biomarkers; Car | 2013 |
Proton pump inhibitors and vascular function: A prospective cross-over pilot study.
Topics: Administration, Oral; Adult; Arginine; Biomarkers; California; Coronary Disease; Cross-Over Studies; | 2015 |
The effects of G-CSF-induced mobilization of progenitor cells are limited by ADMA.
Topics: Aged; Aged, 80 and over; Angina Pectoris; Antioxidants; Arginine; Cells, Cultured; Chromans; Coronar | 2010 |
Symmetrical and asymmetrical dimethylarginine as predictors for mortality in patients referred for coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study.
Topics: Aged; Arginine; Biomarkers; Cardiovascular Diseases; Coronary Angiography; Coronary Disease; Female; | 2011 |
Asymmetrical dimethylarginine (ADMA) and risk of acute coronary events. Does statin treatment influence plasma ADMA levels?
Topics: Acute Disease; Adult; Aged; Arginine; Atorvastatin; Biomarkers; Blood Glucose; Case-Control Studies; | 2003 |
Changes of plasma asymmetric dimethylarginine levels after coronary artery bypass grafting.
Topics: Arginine; Cardiopulmonary Bypass; Coronary Artery Bypass; Coronary Disease; Female; Heart Arrest, In | 2006 |
Effects of a supplement containing isoflavones and Actaea racemosa L. on asymmetric dimethylarginine, lipids, and C-reactive protein in menopausal women.
Topics: Aged; Arginine; C-Reactive Protein; Cholesterol, LDL; Cimicifuga; Coronary Disease; Double-Blind Met | 2007 |
20 other studies available for n(g),n(g')-dimethyl-l-arginine and Coronary Disease
| Article | Year |
|---|---|
Asymmetric Dimethylarginine Predicts One-year Recurrent Cardiovascular Events: Potential Biomarker of "Toxin Syndrome" in Coronary Heart Disease.
Topics: Arginine; Biomarkers; Coronary Disease; Humans; Odds Ratio; Recurrence; Risk Factors; ROC Curve; Syn | 2019 |
Relationship between Dietary Approaches to Stop Hypertension score and Alternative Healthy Eating Index score with plasma asymmetrical dimethylarginine levels in patients referring for coronary angiography.
Topics: Aged; Arginine; Coronary Angiography; Coronary Disease; Coronary Stenosis; Cross-Sectional Studies; | 2015 |
The prediction roles of asymmetric dimethyl-arginine, adiponectin and apelin for macroangiopathy in patients with impaired glucose regulation.
Topics: Adiponectin; Aged; Apelin; Arginine; Atherosclerosis; Blood Glucose; Coronary Disease; Female; Gluco | 2016 |
Stent placement in patients with coronary heart disease decreases plasma levels of the endogenous nitric oxide synthase inhibitor ADMA.
Topics: Aged; Arginine; Cardiovascular Surgical Procedures; Case-Control Studies; Coronary Disease; Down-Reg | 2009 |
Correlation between plasma asymmetric dimethylarginine and different types of coronary heart disease.
Topics: Acute Coronary Syndrome; Aged; Angina Pectoris; Arginine; Biomarkers; Coronary Disease; Female; Huma | 2010 |
Impact of reversible myocardial ischaemia on nitric oxide and asymmetric dimethylarginine production in patients with high risk for coronary heart disease.
Topics: Arginine; Coronary Disease; Diabetes Complications; Exercise Tolerance; Female; Humans; Male; Middle | 2010 |
[Plasma asymmetric dimethylarginine and cystatin C levels in patients with coronary artery disease].
Topics: Aged; Arginine; Case-Control Studies; Coronary Disease; Cystatin C; Female; Humans; Male; Middle Age | 2010 |
Asymmetric and symmetric dimethylarginine and risk of secondary cardiovascular disease events and mortality in patients with stable coronary heart disease: the KAROLA follow-up study.
Topics: Aged; Arginine; Biomarkers; Cause of Death; Chromatography, Liquid; Coronary Disease; Female; Follow | 2013 |
Oestrogen and the cardiovascular system.
Topics: Arginine; Cardiovascular Physiological Phenomena; Coronary Disease; Endothelium, Vascular; Estrogens | 2003 |
Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Arginine; Biomarkers; Chromatography, High Pr | 2003 |
Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of renin-angiotensin system and oxidative stress.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine | 2004 |
Serum homocysteine and endothelial dysfunction in circulatory disorders in women.
Topics: Arginine; Coronary Disease; Endothelium, Vascular; Female; Homocysteine; Humans; Hyperhomocysteinemi | 2004 |
Relationship between obesity, smoking, and the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine.
Topics: Aged; Arginine; Arteriosclerosis; Coronary Disease; Cross-Sectional Studies; Enzyme Inhibitors; Huma | 2004 |
Relations between plasma asymmetric dimethylarginine (ADMA) and risk factors for coronary disease.
Topics: Adult; Aged; Arginine; Biomarkers; Chromatography, High Pressure Liquid; Coronary Angiography; Coron | 2006 |
Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study.
Topics: Adult; Aged; Arginine; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Coronary Disease; Cr | 2005 |
Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study.
Topics: Aged; Arginine; Case-Control Studies; Coronary Disease; Female; Humans; Male; Middle Aged; Risk Fact | 2006 |
Asymmetric dimethylarginine, cortisol/cortisone ratio, and C-peptide: markers for diabetes and cardiovascular risk?
Topics: Arginine; Biomarkers; Blood Glucose; C-Peptide; Case-Control Studies; Coronary Disease; Cortisone; D | 2007 |
Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study).
Topics: Analysis of Variance; Arginine; Biomarkers; Cardiovascular Diseases; Coronary Angiography; Coronary | 2007 |
Asymmetric dimethylarginine, smoking, and risk of coronary heart disease in apparently healthy men: prospective analysis from the population-based Monitoring of Trends and Determinants in Cardiovascular Disease/Kooperative Gesundheitsforschung in der Regi
Topics: Adult; Aged; Arginine; Case-Control Studies; Cell Line; Coronary Disease; Endothelium, Vascular; Fem | 2007 |
Asymmetric dimethylarginine is a marker of poor prognosis and coronary calcium in systemic lupus erythematosus.
Topics: Adult; Antibodies, Antinuclear; Arginine; Biomarkers; Calcinosis; Coronary Angiography; Coronary Dis | 2007 |